Shares of biotech company Celsion (CLSN 1.22%) soared 10% in intraday trading after the company announced an agreement with Chinese drugmaker Zhejiang Hisun Pharmaceutical. With phase 3 clinical trial results for the company's flagship drug, ThermoDox, due to be released before the end of the month, this announcement has added a new dimension to this stock's story. In this video, our health care analysts Max Macaluso and Brenton Flynn break down the details of this agreement and discuss what investors must watch in the coming days.
New Hope for Celsion Investors?
By Max Macaluso and Brenton Flynn – Jan 22, 2013 at 2:35PM
NASDAQ: CLSN
Imunon
Market Cap
$12M
Today's Change
(-1.22%) $0.06
Current Price
$4.85
Price as of October 24, 2025 at 4:00 PM ET
This agreement adds more suspense as investors await Phase 3 clinical trial results from Celsion.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo